# Sun Pharma Advanced Research Company share price today (Sun Pharma Advanced Research Company Ltd, NSE: SPARC)

> Sun Pharma Advanced Research Company share price today: ₹175.74 at the NSE close on 3 November 2026, up 30.0% in a year. Sun Pharma Advanced Research Company (NSE: SPARC) is worth ₹5,719 crore, trades at a P/E of 3.6 and has closed between ₹115.42 and ₹264.60 over the past 52 weeks. > Sun Pharma Advanced Research Company Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SPARC · Pharma - Others · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹175.74 (+30.0% in a year)
- P/E: 3.6×, too little history to compare yet
- Revenue (Jun 2026): ₹40.0 Cr (+300.0% on a year ago)
- Profit (Jun 2026): −₹21.0 Cr
- Operating margin: −85.0% (+455.0 points on a year ago)
- ROCE: 164%, FY26

Biggest thing to watch: the price has already been rising for 24 weeks, so timing is the risk more than the business. ## What is the Sun Pharma Advanced Research Company share price today? Sun Pharma Advanced Research Company Ltd's share price was ₹175.74 at the close on 3 November 2026. It has been rising for 24 weeks. That is 5.0% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 16 weeks running. In the last 52 weeks it traded between ₹115 and ₹265, and at that close it sat 40% of the way up from that low. Over the last 11 years the share price moved −38% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 17 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sun Pharma Advanced Research Company this quarter? One change stood out: operating margin up 455 points on a year earlier. 1. Operating margin up 455 points on a year earlier -85% in the June 2026 quarter, from -540%. ## What are Sun Pharma Advanced Research Company's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Sun Pharma Advanced Research Company reported revenue of ₹40.0 crore, up 300.0% from ₹10.0 crore a year earlier, and a loss of ₹21.0 crore. ### Sun Pharma Advanced Research Company results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹40.0 crore | ₹10.0 crore | +300.0% |
| Profit | loss of ₹21.0 crore | loss of ₹52.0 crore | n/a |
| Earnings per share | ₹−0.64 | ₹−1.60 | n/a |
| Operating margin | −85.0% | −540.0% | +455.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 8 January 2026, about October to December 2025; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Sun Pharma Advanced Research Company share price history? Sun Pharma Advanced Research Company closed at ₹175.74 on 3 November 2026, up 30.0% from ₹135.19 a year earlier (31 October 2025) and down 34.8% over five years. Its highest weekly close since March 2016 was ₹516.05 on 12 January 2018. ### Sun Pharma Advanced Research Company share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹171.75 | +2.3% |
| 1 month ago · 1 Oct 2026 | ₹194.25 | −9.5% |
| 6 months ago · 30 Apr 2026 | ₹143.04 | +22.9% |
| 1 year ago · 31 Oct 2025 | ₹135.19 | +30.0% |
| 3 years ago · 3 Nov 2023 | ₹240.30 | −26.9% |
| 5 years ago · 4 Nov 2021 | ₹269.70 | −34.8% |
| 10 years ago · 4 Nov 2016 | ₹310.85 | −43.5% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹285.26 | −38.4% |
| Highest weekly close since March 2016 · 12 Jan 2018 | ₹516.05 | −65.9% |
| Lowest weekly close since March 2016 · 27 Mar 2020 | ₹95.10 | +84.8% |
| 52-week high (weekly close) · 10 Jul 2026 | ₹264.60 | −33.6% |
| 52-week low (weekly close) · 20 Mar 2026 | ₹115.42 | +52.3% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Sun Pharma Advanced Research Company? 3 Nov 2026: Sun Pharma Advanced Research Company closed at ₹175.74, up 2.3% on the week and down 9.5% on the month. Results for April to June 2026: Revenue up 300.0% on a year earlier. ### Earlier

- 8 Jan 2026: Sun Pharma Advanced Research Company held its results call for October to December 2025. ## What dividend does Sun Pharma Advanced Research Company pay? Sun Pharma Advanced Research Company has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Sun Pharma Advanced Research Company Ltd paid out 0% of its profit as dividends in each of its last 4 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Sun Pharma Advanced Research Company management say on the latest results call? On the call for October to December 2025, held on 8 January 2026, Sun Pharma Advanced Research Company's management spoke about the quarter; the main points are below. > “We are entering the new year with significant momentum on the most important parts of this agenda. Even though we have our fair share of challenges, we're genuinely excited about the potential of our clinical and pre-clinical portfolio as we go into the new year”
> Anil Raghavan, CEO, on the call for October to December 2025

Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/4753-08-Jan-2026.pdf). (From the call for October to December 2025, 8 January 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## Which stock lists is Sun Pharma Advanced Research Company on? Sun Pharma Advanced Research Company is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 5682.536722203332](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Sun Pharma Advanced Research Company profitable? Sun Pharma Advanced Research Company Ltd posted a net loss of ₹21.0 Cr in the Jun 2026 quarter. Full-year FY26 profit was ₹1,553 Cr. That loss is 52.5% of the quarter's revenue. The same quarter a year earlier lost ₹52.0 Cr. 11 of the last 12 reported quarters were loss-making. ## How much revenue does Sun Pharma Advanced Research Company make, and is it growing? Sun Pharma Advanced Research Company Ltd reported ₹40.0 Cr of revenue in the Jun 2026 quarter, +300.0% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 3 years it has grown 98.8% a year on average. The last full year, FY26, came in at ₹1,879 Cr. The last four reported quarters add to ₹1,909 Cr. FY26 revenue was ₹1,879 Cr, +2,509.7% on the year before. Recent pace: the last four quarters grew +1,744.5% on average, against 98.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +2,836.9%, against +426.0% a year over the last 8 quarters (accelerating). ## How much of every ₹100 of sales does Sun Pharma Advanced Research Company keep? Sun Pharma Advanced Research Company Ltd's operating margin was −85.0% in the Jun 2026 quarter, 455.0 percentage points higher than the same quarter a year ago. Across 4 years it has been between −532.0% and 85.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +455.1 percentage points on the year while gross margin changed +34.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Sun Pharma Advanced Research Company's profit turning into cash? Sun Pharma Advanced Research Company Ltd's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used ₹239 Cr of cash, against ₹1,553 Cr of profit. After ₹14.0 Cr of spending on assets, free cash was −₹253 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the bigger use of cash is spending on new assets, at 1.7× depreciation over three years. The next section checks what that spending is building. ## Where does Sun Pharma Advanced Research Company's cash go? Sun Pharma Advanced Research Company Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 2 days in FY26, down from 50 days in FY23. It spent ₹59.0 Cr on assets over the last 3 years. At FY26 sales of ₹1,879 Cr, each day of that cycle ties up about ₹5.1 Cr, so roughly ₹10.0 Cr is tied up in the business at any time. Spending on assets: ₹59.0 Cr over the last 3 years, against ₹35.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹72.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Sun Pharma Advanced Research Company's P/E ratio, and how does it compare with its own history? Sun Pharma Advanced Research Company Ltd's P/E is 3.6×, with too little history to compare. Its usual P/E (the middle reading) is 4.3×, over 5 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Sun Pharma Advanced Research Company business getting better or worse? Sun Pharma Advanced Research Company Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Sun Pharma Advanced Research Company earn on its capital? Sun Pharma Advanced Research Company Ltd earned a ROCE of 164% in FY26. That is up from a low of −279% in FY25. Its return on capital used (ROIC) is 126.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 82.7% net margin and 0.87× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 82.7% net margin × 0.87× asset turnover × 1.62× leverage (assets divided by equity) ≈ 116.6% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 138.2% − 12.0% = +126.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. ## Does Sun Pharma Advanced Research Company have too much debt? Sun Pharma Advanced Research Company Ltd has total debt of ₹559 Cr against shareholder equity of ₹1,339 Cr as of Jun 2026, so its debt is 0.42× its equity. Year by year, that ratio went from 2.55 in FY22 to 0.42 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Sun Pharma Advanced Research Company shareholding pattern? Foreign institutions raised their stake in Sun Pharma Advanced Research Company Ltd by 1.5 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 3.7% of the company. Domestic institutions moved −0.5 points over the same period, to 0.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +1.5 points over 8 quarters, to 3.7%; Domestic institutions: −0.5 points over 8 quarters, to 0.1%; Promoters: +0.0 points over 8 quarters, to 65.7%. Why the owners changed: foreign institutions drove it (+1.5 points), with the other side taken by domestic institutions (−0.5 points). They raised their stake step by step. ## How far is Sun Pharma Advanced Research Company from balance-sheet trouble? For Sun Pharma Advanced Research Company Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sun Pharma Advanced Research Company rank in its industry? 61.1 out of 100, rank 3 of 10 in Pharma - Others, with 78% of the evidence available. Sun Pharma Advanced Research Company Ltd scores 61.1 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 3. Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%. The four parts add up to the total exactly: 25.8 + 16 + 15 + 4.3 = 61.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sun Pharma Advanced Research Company compared with? Sun Pharma Advanced Research Company ranks 3 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 61.1 out of 100. 1. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) SYNCOMF · breaking out · Most evidence points up · 89% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 0.4% · Profit 48.3% · Operating margin change 7 points · 88% evidence Capital efficiency 17.2/25 · ROCE 24.7% · Operating margin 21% · 100% evidence Valuation 15.1/20 · P/E 21.2× · PEG 0.79 · 65% evidence Relative strength 17.8/20 · Lead over its industry -0.2% · Lead over NIFTY 500 32.3% · 1 year 16.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 17.2 + 15.1 + 17.8 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) SHUKRAPHAR · breaking out · Too little evidence to rank firmly · 56% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 100% · Profit 100% · Operating margin change 66 points · 83% evidence Capital efficiency 19.4/25 · ROCE 37% · Operating margin 90% · 76% evidence Valuation 9.3/20 · P/E 91.9× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 83.7% · 1 year 82.8% · 25% evidence · 6 of 6 weeks ahead Exact sum: 28.5 + 19.4 + 9.3 + 12.5 = 69.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. Sun Pharma Advanced Research Company Ltd this page SPARC · quiet · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 100% · Profit 100% · Operating margin change 455 points · 65% evidence Capital efficiency 16.0/25 · ROCE 164% · Operating margin -85% · 100% evidence Valuation 15.0/20 · P/E 3.6× · PEG n/a · 50% evidence Relative strength 4.3/20 · Lead over its industry -17.4% · Lead over NIFTY 500 9.3% · 1 year 30.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25.8 + 16 + 15 + 4.3 = 61.1 · What this means: Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%. 4. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) REMUS · breaking out · Too little evidence to rank firmly · 54% evidence 54.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 57.3% · Profit 80% · Operating margin change -4 points · 27% evidence Capital efficiency 13.3/25 · ROCE 11.5% · Operating margin 32% · 57% evidence Valuation 11.2/20 · P/E 41.2× · PEG n/a · 50% evidence Relative strength 12.8/20 · Lead over its industry -12.6% · Lead over NIFTY 500 16.6% · 1 year 17.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.5 + 13.3 + 11.2 + 12.8 = 54.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) TTKHLTCARE · quiet · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 6.8/25 · ROCE 8% · Operating margin 1.6% · 100% evidence Valuation 15.7/20 · P/E 17.6× · PEG 1.38 · 100% evidence Relative strength 8.4/20 · Lead over its industry n/a · Lead over NIFTY 500 -3% · 1 year -23.1% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19.8 + 6.8 + 15.7 + 8.4 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) UNICHEMLAB · losing its lead · Evidence leans down · 64% evidence 38.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.4/35 · Revenue 7.2% · Profit 100% · Operating margin change 6.7 points · 62% evidence Capital efficiency 6.6/25 · ROCE 4.1% · Operating margin 11% · 76% evidence Valuation 10.0/20 · P/E 27.9× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -13.3% · Lead over NIFTY 500 15.4% · 1 year 2.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.4 + 6.6 + 10 + 8.3 = 38.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) PANACEABIO · basing · Most evidence points down · 76% evidence 20.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.2/35 · Revenue 10.3% · Profit -80% · Operating margin change 3.5 points · 88% evidence Capital efficiency 1.2/25 · ROCE -2.4% · Operating margin 2.8% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 1.0/20 · Lead over its industry -38.3% · Lead over NIFTY 500 -16.4% · 1 year -28.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 8.2 + 1.2 + 10 + 1 = 20.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) leader · Too little evidence to rank firmly · 48% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.1/43.75 · Revenue 100% · Profit 100% · Operating margin change 53.1 points · 62% evidence Capital efficiency 19.4/31.25 · ROCE 16.8% · Operating margin 44.7% · 95% evidence Valuation 11.1/25 · P/E 219× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.1 + 19.4 + 11.1 = 61.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) Too little evidence to rank firmly · 47% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidence Capital efficiency 21.8/31.25 · ROCE 27.2% · Operating margin 32% · 71% evidence Valuation 14.3/25 · P/E 13.2× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.6 + 21.8 + 14.3 = 56.7 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) MADHUVEER · Too little evidence to rank firmly · 33% evidence 42.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.5/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidence Capital efficiency 11.7/31.25 · ROCE -1.1% · Operating margin 69.7% · 57% evidence Valuation 10.6/25 · P/E 660× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.5 + 11.7 + 10.6 = 42.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Others](https://www.sectoralpha.in/sectors/pharma-others), all 10 compared on one page. ## Which companies are close to Sun Pharma Advanced Research Company in size? Sun Pharma Advanced Research Company is the largest of 10 Pharma - Others companies on Sector Alpha by market value (scores of 30 October 2026). It is the largest. Just below it: Unichem Laboratories, Shukra Pharmaceuticals, Panacea Biotec, Syncom Formulations (India), JOJO and TTK Healthcare. ### Pharma - Others companies close in size

1. Sun Pharma Advanced Research Company Ltd ₹5,727 crore
2. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) ₹3,406 crore
3. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) ₹3,313 crore
4. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) ₹1,919 crore
5. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) ₹1,809 crore
6. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) ₹1,539 crore
7. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) ₹1,279 crore

[All 10 Pharma - Others companies, largest first](https://www.sectoralpha.in/sectors/pharma-others#all-companies)

### Companies close in size in other industries

1. [Campus Activewear Ltd](https://www.sectoralpha.in/stocks/campus-activewear-ltd) ₹5,834 crore · Footwear
2. [Safari Industries (India) Ltd](https://www.sectoralpha.in/stocks/safari-industries-indialtd) ₹5,787 crore · Travel Bags
3. Sun Pharma Advanced Research Company Ltd ₹5,727 crore
4. [Redtape Ltd](https://www.sectoralpha.in/stocks/redtape-ltd) ₹5,724 crore · Footwear
5. [Balaji Amines Ltd](https://www.sectoralpha.in/stocks/balaji-amines-ltd) ₹5,721 crore · Chemicals - Organic

## What else do people ask about Sun Pharma Advanced Research Company? ### What is Sun Pharma Advanced Research Company's share price today? Sun Pharma Advanced Research Company Ltd's share price is ₹175.74, +30.0% over the past year. The whole company is worth ₹5,719 Cr on the market. In the last 52 weeks it traded between ₹115 to ₹265; today it is 40% of the way up from the low, 5.0% below its 200-day average (as of 3 November 2026). ### What were Sun Pharma Advanced Research Company's latest quarterly results? Sun Pharma Advanced Research Company Ltd reported revenue of ₹40.0 Cr and a net loss of ₹21.0 Cr for the Jun 2026 quarter. Earnings per share were −₹0.64. The operating margin was −85.0%, 455.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Sun Pharma Advanced Research Company's market cap? Sun Pharma Advanced Research Company Ltd's market capitalisation is ₹5,719 Cr at a share price of ₹175.74. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Sun Pharma Advanced Research Company performing? Sun Pharma Advanced Research Company Ltd's share price has been rising for 24 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 16 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Sun Pharma Advanced Research Company's share price go up? This page does not forecast Sun Pharma Advanced Research Company Ltd's share price. What it shows instead: the share price is ₹175.74, and it has been rising for 24 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Who owns Sun Pharma Advanced Research Company? Promoters own 65.7% of Sun Pharma Advanced Research Company Ltd, foreign institutions 3.7%, domestic institutions 0.1% and the public 30.5% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 1.5 percentage points over 8 quarters (as of 3 November 2026). ### Does Sun Pharma Advanced Research Company have too much debt? Sun Pharma Advanced Research Company Ltd has a moderate amount of debt: its debt is 0.42× its equity, and its operating profit is 47 times its interest bill. FY26 borrowings were ₹559 Cr against equity of ₹1,338 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Sun Pharma Advanced Research Company in its business cycle? Sun Pharma Advanced Research Company Ltd's FY26 operating margin was 85.0%, against a 4-year range of −532.0% to 85.0%: the middle of its own range, neither a peak nor a low. The latest quarter was −85.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Sun Pharma Advanced Research Company story? Biggest thing to watch: the price has already been rising for 24 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Sun Pharma Advanced Research Company a stock worth studying right now? What the numbers show: Sun Pharma Advanced Research Company Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.